IMPORTANCE Prevention of iron deficiency in infancy may promote neurodevelopment. Delayed cord clamping (DCC) can prevent iron deficiency during the first 6 months of life. However, no data are available on long-term effects on infant outcomes in relation to time for umbilical cord clamping.
I mmediately after birth, the newborn infant still shares its blood circulation with the placenta and umbilical cord. As the arteries in the umbilical cord start to constrict, uterine contractions contribute with a net inflow of blood from the placenta into the newborn, totaling approximately 30% extra blood volume. 1 This transfusion will be impaired if immediate or early cord clamping (ECC) is performed, while a delay in clamping for 2 to 3 minutes will allow for a full transfusion. This placental transfusion has been shown to result in an increased hemoglobin (Hb) level and hematocrit in the neonatal period. 2 During the last decade, several studies have shown that the increased blood volume after delayed cord clamping (DCC) also contributes to higher ferritin levels at 4 to 6 months of life and possibly also helps to prevent infant iron deficiency (ID). 3, 4 In animal models, ID has repeatedly been shown to affect dopamine metabolism, myelination, and energy metabolism. 5, 6 In infancy, ID has also been associated with impaired neurodevelopment, including both gross motor function and fine motor development, and adverse behavior. 7 Iron supplementation to populations with increased risk for ID improves psychomotor outcome in infancy and reduces behavioral problems. 8, 9 We previously demonstrated in a randomized clinical trial that DCC, as compared with ECC, is associated with a higher neonatal Hb level and a lower rate of neonatal anemia as well as a higher ferritin level and less ID at age 4 months. 10 No adverse effects of the intervention were found. 10, 11 At age 4 months, the infants in the 2 groups had a comparable incidence of symptoms of infection and similar neurodevelopment. 12 We hypothesized that DCC after delivery has long-lasting effects and that it improves iron status and neurodevelopment at age 12 months.
Methods
This study is a secondary analysis of a randomized clinical trial conducted at the Hospital of Halland, Halmstad, Sweden. The trial was approved by the Regional Ethical Review Board of Lund University. In short, pregnant women were considered eligible if they were nonsmoking, healthy, and carrying a lowrisk singleton pregnancy with an expected vaginal delivery at term, as previously described. 10 They were informed about the study at antenatal care units in the area around Halmstad. After written informed parental consent was obtained and when delivery was imminent, 400 newborn infants were randomized to DCC at 180 seconds or more after delivery or to ECC before or at 10 seconds after birth, as previously described (Figure) . 10 Neither the mother giving birth nor the midwife performing the intervention could be blinded, but all staff involved in collection or analyses of blood samples or administration of the Ages and Stages Questionnaire, second edition (ASQ) were blinded to the allocation group. Early cord clamping was the standard method at the hospital during the inclusion period between April 16, 2008, and May 22, 2009 . Infants were scheduled for follow-up visits at ages 4 and 12 months.
Outcomes
The primary outcome of this randomized clinical trial was the ferritin level at age 4 months, as previously reported. 
12-Month Follow-up
The follow-up visit included blood sampling, weight measurement, and length measurement. Venous blood sampling was performed after application of a local anesthetic (lidocaine, 2.5%, and prilocaine, 2.5%). One month before the planned 12-month visit, parents received a letter with the ASQ and a 3-day food diary.
Blood Samples
Blood samples were analyzed for the following: complete blood cell count (Hb level, hematocrit, and MCV), iron status (serum ferritin level, TS, and sTfR level), and C-reactive protein (CRP) level. Blood samples for complete blood cell counts were collected in ethylenediaminetetraacetic acid (EDTA) tubes (BD Vacutainer) and analyzed using the automated hematology analyzer Sysmex XE 2100 (Sysmex). Iron status indicators and CRP were collected in serum separator tubes (BD Vacutainer) and analyzed using a Cobas 6000 analyzer (Roche Diagnostics). Anemia was defined as an Hb level lower than 11.0 g/dL (to convert to grams per liter, multiply by 10.0). Low MCV, ferritin level, and TS were defined as MCV lower than 70 fL, ferritin level lower than 12 ng/mL (to convert to picomoles per liter, multiply by 2.247), and TS less than 10%, respectively. 13 We defined the upper reference limit for sTfR (5.9 mg/L) by the mean value plus 2 SDs of the values from the 330 study participants with no anemia and normal MCV, ferritin level, and TS. Iron deficiency was defined as at least 2 of 4 iron store indicators (ferritin level, TS, sTfR level, MCV) outside reference values. Iron deficiency anemia was defined as anemia in combination with ID. 14 As inflammation is known to influence iron status markers, 15 blood samples with a CRP concentration of 10 mg/L or greater (to convert to nanomoles per liter, multiply by 9.524) were excluded from analysis.
Ages and Stages Questionnaire
The ASQ 16 was used to assess parent-reported infant development. Permission was obtained from Paul H. Brookes Publishing Co to translate the ASQ 12-month questionnaire to Swedish for use in the study. We created cutoff scores according to the ASQ manual, ie, by subtracting the mean score with 2 SDs. If the ASQs were not completely answered, scores were adjusted according to the ASQ manual.
Sample Size
The sample size for the primary outcome at 4 months was estimated to find a difference of 29% in geometric mean serum ferritin level between the 2 randomization groups with a power of 80% and a significance level of P < .05. A post hoc analysis of the 12-month data showed that a difference between the 2 groups of 7.5% in geometric mean ferritin level and a 12-point difference in the ASQ total score were needed to reach statistical significance (with a type I error rate of .05 and power of 80%).
Statistical Analysis
Data were analyzed both according to intention to treat and per protocol. For comparisons, t test, Mann-Whitney U test, and Fisher exact test were used as appropriate. For 95% confidence interval across groups, the Hodges-Lehmann estimator was used. Ferritin was log 10 transformed for analysis. We used SPSS for Windows, version 18.0 (SPSS Inc). Relative risks and 95% confidence intervals were calculated by the webbased JavaStat calculator. 17 Calculations of Spearman rank correlation coefficient (ρ) were used to determine neonatal and 4-month variables that were associated with outcomes at 12 months (ferritin level and ASQ total score). Variables with a correlation significance of P < .05 for each outcome were then entered into a linear regression model and analyzed by stepwise backward selection, leaving only variables with P < .05 in the model.
Results
At 12 months, 347 of 382 infants (90.8%) returned for blood sampling and/or were assessed by the ASQ. Blood samples were collected from 337 of 382 infants (88.2%), of whom 174 of 193 (90.2%) belonged to the DCC group and 163 of 189 (86.2%) to the ECC group (P = .27) at a mean (SD) age of 366 (8) Baseline and background characteristics are presented in Table 1 . Altogether, ASQ data were obtained for 340 infants (89.0%) with a completed ASQ, including 172 of 193 infants (89.1%) in the DCC group vs 168 of 189 infants (88.9%) in the ECC group (P > .99) (Figure) . The date for answering the ASQ was given by 307 parents, showing that infants were a mean (SD) of 363 (9) days old when the assessments were done, with no difference between the groups (mean [SD] age, 362 [10] days for the DCC group vs 364 [8] days for the ECC group; P = .14). Data were excluded if blood sampling or the ASQ was done more than 1 calendar month before or after the infant reached age 12 months. For this reason, 1 blood sample in the DCC group was excluded, as were 3 sets of ASQ data (2 in the DCC group and 1 in the ECC group). A total of 32 blood samples with a CRP level of 10 mg/L or greater (9.5%) were excluded from analysis, including 11 (6.7%) in the ECC group and 21 (12.1%) in the DCC group (P = .10). There were no differences between the 2 groups in Hb level or any of the iron status indicators at 12 months ( Table 2 ). The proportions of cases outside reference ranges for anemia and iron store indicators did not differ between the groups ( Table 2 ). The results did not change when data were analyzed per protocol.
Neurodevelopment at 12 months did not differ between the groups for the ASQ total score or 5 subdomain scores or for the proportion of infants below the cutoff level ( Table 3) . The results did not change when data were analyzed per protocol. In univariate analyses, ferritin level at 12 months showed significant positive correlations with umbilical cord ferritin Table 4) . Variables at 4 months with significant correlations with 12-month ferritin level included iron status indicators (positive correlation) and body weight (negative correlation).
Variables at 12 months that correlated with 12-month ferritin levels were body weight and nutritional intake (negative correlations) and the infant's age at blood sampling (positive correlation) ( Table 1) . The ASQ total score at 12 months was positively associated with female sex, Apgar score at 5 minutes, and breastfeeding within the first hour of life. None of these variables differed between the 2 randomization groups (Table 1) . Infant age at testing, within the interval of 11 to 13 months, positively correlated with ASQ score. In multivariate linear regression analysis, infant sex, breastfeeding within the first hour of life, and postnatal age at testing remained significant predictors for ASQ score at 12 months (Table 4) . In univariate analyses, the 12-month ASQ did not correlate with gestational age, birth weight, Hb level, or any of the iron status indicators in umbilical cord blood. The ASQ total score at 12 months correlated with the ASQ score at 4 months (ρ = 0.401; P < .001; n = 337), while breastfeeding at 4 months had no effect on the ASQ score at 12 months (Table 1) .
Because infant sex correlated independently with both ferritin level and ASQ score at 12 months, sex and randomization group were entered as variables in an analysis of covariance model. No interaction was found in the model concerning the 12-month ferritin level, but in the ASQ model there was a significant interaction. Randomization to DCC compared with ECC was associated with a 12-point-lower ASQ score for girls (mean [SD] 
Discussion
We previously demonstrated, in a randomized clinical trial, that DCC for 3 minutes or more increases neonatal Hb and IgG levels and improves iron stores at age 4 months without noticeable adverse effects. 10, 12 In this study, we assessed the same cohort of term-born infants at age 12 months. We hypothesized that the improved iron status at age 4 months would prevent ID at age 12 months and also promote infant neurodevelopment. However, we were unable to demonstrate any differences in iron status and in neurodevelopment between the randomization groups at 12 months. Delayed cord clamping adds about 30% extra blood volume to the newborn. As the red blood cells undergo hemolysis, the hemoglobin is metabolized to enrich the infant's iron stores; consequently, DCC increases iron stores at ages 4 to 6 months and also seems to prevent ID at age 4 months. Except for 1 small study (n = 28), published in 1941, 18 that demonstrated a higher mean corpuscular Hb level in 8-to 10-monthold infants subjected to DCC, no study investigating effects of timing for umbilical cord clamping has, to our knowledge, a longer follow-up period than 6 months. In this study, iron stores were assessed by different indicators of iron status: Hb level, MCV, reticulocyte Hb level, ferritin level, TS, and sTfR level. Even when comparing the levels of each of these indicators, we could not demonstrate any differences in iron status between the 2 randomization groups. We also examined the proportion of infants with ID in our population by using a combination of 4 iron status indicators (ferritin level, MCV, TS, and sTfR level), but no significant difference was found in the proportion of ID between the 2 groups. We found that ferritin level in umbilical cord blood was a strong predictor of ferritin level at age 12 months.
Iron deficiency is associated with serious complications such as ID anemia and suboptimal neurodevelopment, 19 and iron substitution in infancy prevents ID anemia and improves neurodevelopment. 8 As for ID anemia, we did only find 1 infant fulfilling the criteria for this condition at age 12 months, and although this infant belonged to the ECC group, this finding is not associated with a significant difference between groups. In this study, the prevalence of ID at age 12 months, defined as a serum ferritin level lower than 12 ng/mL, was much lower (1.7%) than in a previous Swedish study (26%) published in 1998. 20 A national recommendation that emphasized avoidance of cow's milk as a beverage and promoted ironfortified cereals during the second half of the first year may b Variables entered in the model for the ASQ included sex; Apgar score at 5 minutes; breastfeeding within 1 hour after birth; and age of the infant at the 12-month ASQ (F = 10.8; P < .001; R 2 = 0.103).
